These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24252054)

  • 1. Confirmation of effectiveness of tocilizumab by ultrasonography and magnetic resonance imaging in biologic agent-naïve early-stage rheumatoid arthritis patients.
    Kawashiri SY; Suzuki T; Nakashima Y; Horai Y; Okada A; Iwamoto N; Ichinose K; Tamai M; Arima K; Nakamura H; Origuchi T; Uetani M; Aoyagi K; Kawakami A
    Mod Rheumatol; 2015; 25(6):948-53. PubMed ID: 24252054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
    Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
    Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
    Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
    Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
    Kawashiri SY; Arima K; Suzuki T; Nakashima Y; Horai Y; Okada A; Tamai M; Nakamura H; Kawakami A
    Mod Rheumatol; 2014 Jul; 24(4):681-4. PubMed ID: 24533548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
    Peterfy C; Kremer J; Rigby W; Singer N; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
    J Rheumatol; 2020 Mar; 47(3):325-332. PubMed ID: 31154414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalized estimating equation model to compare drug effects on synovitis of the dominant wrist in severe rheumatoid arthritis between tocilizumab versus adalimumab versus abatacept using high-resolution ultrasound.
    Chen YC; Chiu WC; Su FM; Chen JF
    Int J Rheum Dis; 2018 Sep; 21(9):1695-1700. PubMed ID: 29024421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
    Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
    J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study.
    Døhn UM; Ejbjerg B; Boonen A; Hetland ML; Hansen MS; Knudsen LS; Hansen A; Madsen OR; Hasselquist M; Møller JM; Ostergaard M
    Ann Rheum Dis; 2011 Feb; 70(2):252-8. PubMed ID: 20980282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-articular methotrexate versus corticosteroid injections in medium-sized joints of rheumatoid arthritis patients-an intervention study.
    Mortada MA; Abdelwhab SM; Elgawish MH
    Clin Rheumatol; 2018 Feb; 37(2):331-337. PubMed ID: 28963634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced ultrasonography is more sensitive than grayscale and power Doppler ultrasonography compared to MRI in therapy monitoring of rheumatoid arthritis patients.
    Ohrndorf S; Hensch A; Naumann L; Hermann KG; Scheurig-Münkler C; Meier S; Burmester GR; Backhaus M
    Ultraschall Med; 2011 Dec; 32 Suppl 2():E38-44. PubMed ID: 22052070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis.
    Bensaoud N; Rostom S; Bahiri R; Hajjaj-Hassouni N
    Clin Rheumatol; 2015 Jun; 34(6):1031-7. PubMed ID: 25903819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
    Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
    Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active synovitis in the presence of osteitis predicts residual synovitis in patients with rheumatoid arthritis with a clinical response to treatment.
    Fukae J; Tanimura K; Isobe M; Kitano A; Henmi M; Nakai M; Aoki Y; Sakamoto F; Narita A; Ito T; Mitsuzaki A; Matsuhashi M; Shimizu M; Kamishima T; Atsumi T; Koike T
    Int J Rheum Dis; 2018 Oct; 21(10):1809-1814. PubMed ID: 28160411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis.
    Hammer HB; Hansen I; Järvinen P; Leirisalo-Repo M; Ziegelasch M; Agular B; Terslev L
    Scand J Rheumatol; 2021 Jul; 50(4):262-270. PubMed ID: 33464147
    [No Abstract]   [Full Text] [Related]  

  • 15. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study.
    Ishiguro N; Atsumi T; Harigai M; Mimori T; Nishimoto N; Sumida T; Takeuchi T; Tanaka Y; Nakasone A; Takagi N; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):217-226. PubMed ID: 27414105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.
    Hirota T; Suzuki T; Ogishima H; Hagiwara S; Ebe H; Takahashi H; Yokosawa M; Umeda N; Kondo Y; Tsuboi H; Matsumoto I; Sumida T
    Mod Rheumatol; 2016; 26(1):29-35. PubMed ID: 26140463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
    Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
    Peterfy C; DiCarlo J; Emery P; Genovese MC; Keystone EC; Taylor PC; Schlichting DE; Beattie SD; Luchi M; Macias W
    J Rheumatol; 2019 Aug; 46(8):887-895. PubMed ID: 30647190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.